tetano
Editor, Senior Moderator
Aging (Albany NY)
. 2020 Nov 16;12.
doi: 10.18632/aging.104019. Online ahead of print.
Clinical characteristics and fatal outcomes of hypertension in patients with severe COVID-19
Xiaocheng Cheng[SUP] 1 [/SUP], Guoqiang Cai[SUP] 2 [/SUP], Xuesong Wen[SUP] 1 [/SUP], Lei Gao[SUP] 1 [/SUP], Dan Jiang[SUP] 1 [/SUP], Min Sun[SUP] 1 [/SUP], Shu Qin[SUP] 1 [/SUP], Jianzhong Zhou[SUP] 1 [/SUP], Dongying Zhang[SUP] 1 [/SUP]
Affiliations
Abstract
The aim of this study is to investigate clinical characteristics and fatal outcomes of hypertension as well as the role of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARB) use in patients with severe coronavirus disease 2019 (COVID-19). A total of 220 (female: 51.8%) patients with severe COVID-19 were included. The mean age of included patients was 59.5 years and 70 (31.8%) patients had a history of hypertension. There were 23 patients (32.9%) receiving ACEI/ARB therapy. Patients with hypertension were older and had more comorbidities, and were more likely to suffer from severe inflammatory response and acute cardiac injury. Moreover, patients with hypertension were associated with significantly higher risk of in-hospital mortality than patients without hypertension. After adjustment of potential confounders, the independent correlation was still observed. In addition, ACEI/ARB users were associated with lower level of high-sensitivity cardiac troponin I and creatinine kinase-myocardial band, and lower risk of acute cardiac injury than ACEI/ARB non-users. In conclusion, patients with hypertension were more likely to suffer from severe inflammatory response, acute cardiac injury and had high risk of in-hospital mortality in severe COVID-19. The use of ACEI/ARB may protect patients with COVID-19 from acute cardiac injury.
Keywords: ACEI/ARB; COVID-19; cardiac injury; hypertension; mortality.
. 2020 Nov 16;12.
doi: 10.18632/aging.104019. Online ahead of print.
Clinical characteristics and fatal outcomes of hypertension in patients with severe COVID-19
Xiaocheng Cheng[SUP] 1 [/SUP], Guoqiang Cai[SUP] 2 [/SUP], Xuesong Wen[SUP] 1 [/SUP], Lei Gao[SUP] 1 [/SUP], Dan Jiang[SUP] 1 [/SUP], Min Sun[SUP] 1 [/SUP], Shu Qin[SUP] 1 [/SUP], Jianzhong Zhou[SUP] 1 [/SUP], Dongying Zhang[SUP] 1 [/SUP]
Affiliations
- PMID: 33197882
- DOI: 10.18632/aging.104019
Abstract
The aim of this study is to investigate clinical characteristics and fatal outcomes of hypertension as well as the role of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARB) use in patients with severe coronavirus disease 2019 (COVID-19). A total of 220 (female: 51.8%) patients with severe COVID-19 were included. The mean age of included patients was 59.5 years and 70 (31.8%) patients had a history of hypertension. There were 23 patients (32.9%) receiving ACEI/ARB therapy. Patients with hypertension were older and had more comorbidities, and were more likely to suffer from severe inflammatory response and acute cardiac injury. Moreover, patients with hypertension were associated with significantly higher risk of in-hospital mortality than patients without hypertension. After adjustment of potential confounders, the independent correlation was still observed. In addition, ACEI/ARB users were associated with lower level of high-sensitivity cardiac troponin I and creatinine kinase-myocardial band, and lower risk of acute cardiac injury than ACEI/ARB non-users. In conclusion, patients with hypertension were more likely to suffer from severe inflammatory response, acute cardiac injury and had high risk of in-hospital mortality in severe COVID-19. The use of ACEI/ARB may protect patients with COVID-19 from acute cardiac injury.
Keywords: ACEI/ARB; COVID-19; cardiac injury; hypertension; mortality.